Rosstat (the Federal State Statistics Service) has recorded an increase in prices for a number of VED-listed medicines in February 2023. The drugs that demonstrated the most significant price growth are furosemide (3.7%), ibuprofen (1.5%), and acetylsalicylic acid (1.4%), with the average price increase of 0.3%.
Prices for ascorbic acid, omeprazole, drotaverine, sodium chloride, amoxicillin with clavulanic acid, oseltamivir, and colecalciferol also increased by 0.7% to 1.3%.
Rosstat’s report also mentions a decrease in the price of some goods. These are, in particular, Grippferon (1%), Suprastin (0.7%), hydrogen peroxide (0.6%), Azithromycin (0.5%), Smecta and Xarelto (0.4%).
Boris Titov, the business ombudsman of the Russian Federation, had recommended to develop measures that would not violate the rights of entrepreneurs and would eliminate the need to sell VED at prices below the purchase price, but the Antimonopoly Service considered that an attempt by market participants to circumvent the current pricing system.